Kouanfack C., Sanchez T. T., Wandji M. L., Mpoudi-Etame M., Bassega P. O., Perrineau S., Bwenda T. A., Tata D. T., Tongo M., Varloteaux Marie, Montoyo A., Peeters Martine, Reynes J., Calmy A., Delaporte E., NAMSAL ANRS 12313 Study Group. (2020). Dolutegravir- versus low-dose Efavirenz-based regimen for the initial treatment of HIV-1 infection in Cameroon : week 96 results of the ANRS 12313-NAMSAL trial. Journal of the International AIDS Society, 23 (4), p. 17-18.
Titre du document
Dolutegravir- versus low-dose Efavirenz-based regimen for the initial treatment of HIV-1 infection in Cameroon : week 96 results of the ANRS 12313-NAMSAL trial
Kouanfack C., Sanchez T. T., Wandji M. L., Mpoudi-Etame M., Bassega P. O., Perrineau S., Bwenda T. A., Tata D. T., Tongo M., Varloteaux Marie, Montoyo A., Peeters Martine, Reynes J., Calmy A., Delaporte E., NAMSAL ANRS 12313 Study Group
Source
Journal of the International AIDS Society, 2020,
23 (4), p. 17-18